{"entity":{"id":"nct06058377","kind":"trial","name":"Durvalumab with chemotherapy in high-risk early breast cancer","aka":["Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer"],"tldr":"This study compares usual chemotherapy with or without durvalumab in a selected high-risk group of early breast cancers. It asks whether adding immune treatment lowers the chance of a cancer-related event.","summary":"This study compares usual chemotherapy with or without durvalumab in a selected high-risk group of early breast cancers. It asks whether adding immune treatment lowers the chance of a cancer-related event.\n\nInterventional study registered as NCT06058377, sponsored by National Cancer Institute (NCI). Registry phase: 3. Registry enrollment is 3,680 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT06058377","url":"https://clinicaltrials.gov/study/NCT06058377"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT06058377"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","doxorubicin","durvalumab","paclitaxel"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06058377","phase":"3","setting":"Stage II to III hormone receptor-positive, HER2-negative breast cancer with MammaPrint High 2 risk","sponsor":"National Cancer Institute (NCI)","participation":[{"nct":"NCT06058377","source":"https://clinicaltrials.gov/study/NCT06058377","fetchedAt":"2026-10-10T20:54:20.454521Z","studySha256":"3bf0b6c83fae8394e2a00b0148439a059a1cedae51c7a920d456aaf9df16ad89","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-09","leadSponsor":"National Cancer Institute (NCI)","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":3680,"enrolmentType":"ESTIMATED","siteCount":561,"recruitingSiteCount":542,"countries":["Puerto Rico","United States"]}],"started":"2023-11-27","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06058377/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}